Citadel Advisors’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-236,500
Closed -$20.1M 11879
2020
Q3
$20.1M Sell
236,500
-303,300
-56% -$15.3M 0.01% 1560
2020
Q2
$19.1M Buy
539,800
+333,400
+162% +$9.75M 0.01% 1543
2020
Q1
$2.78M Sell
206,400
-520,000
-72% -$8.75M ﹤0.01% 3582
2019
Q4
$15.4M Sell
726,400
-173,400
-19% -$3.06M 0.01% 1745
2019
Q3
$11.9M Sell
899,800
-43,600
-5% -$641K 0.01% 2011
2019
Q2
$13.1M Buy
943,400
+343,900
+57% +$5.17M 0.01% 1861
2019
Q1
$11.5M Buy
599,500
+148,000
+33% +$2.39M 0.01% 1904
2018
Q4
$6.44M Buy
451,500
+275,100
+156% +$5.46M ﹤0.01% 2443
2018
Q3
$3.67M Sell
176,400
-73,100
-29% -$1.73M ﹤0.01% 3418
2018
Q2
$5.91M Buy
249,500
+86,900
+53% +$1.75M ﹤0.01% 2544
2018
Q1
$2.38M Sell
162,600
-178,700
-52% -$2.92M ﹤0.01% 3470
2017
Q4
$5.51M Buy
341,300
+63,100
+23% +$745K ﹤0.01% 2368
2017
Q3
$3.89M Buy
278,200
+88,500
+47% +$882K ﹤0.01% 2577
2017
Q2
$1.68M Buy
189,700
+24,300
+15% +$171K ﹤0.01% 3400
2017
Q1
$1.07M Buy
165,400
+30,700
+23% +$156K ﹤0.01% 3894
2016
Q4
$494K Buy
134,700
+19,600
+17% +$58K ﹤0.01% 4913
2016
Q3
$374K Buy
115,100
+18,700
+19% +$52.3K ﹤0.01% 5322
2016
Q2
$224K Buy
96,400
+66,100
+218% +$221K ﹤0.01% 5663
2016
Q1
$76K Sell
30,300
-117,500
-79% -$264K ﹤0.01% 6136
2015
Q4
$454K Buy
147,800
+21,900
+17% +$61.1K ﹤0.01% 4589
2015
Q3
$217K Sell
125,900
-174,900
-58% -$446K ﹤0.01% 6042
2015
Q2
$1.22M Buy
300,800
+141,000
+88% +$576K ﹤0.01% 3713
2015
Q1
$612K Buy
159,800
+47,900
+43% +$208K ﹤0.01% 4619
2014
Q4
$537K Buy
111,900
+31,700
+40% +$125K ﹤0.01% 4631
2014
Q3
$298K Buy
80,200
+5,500
+7% +$18.6K ﹤0.01% 5269
2014
Q2
$273K Buy
74,700
+34,900
+88% +$128K ﹤0.01% 5180
2014
Q1
$168K Sell
39,800
-50,900
-56% -$252K ﹤0.01% 5706
2013
Q4
$417K Buy
90,700
+48,900
+117% +$218K ﹤0.01% 4230
2013
Q3
$259K Sell
41,800
-11,000
-21% -$63.3K ﹤0.01% 4510
2013
Q2
$287K Buy
+52,800
New +$173K ﹤0.01% 4346

Citadel Advisors's IMMU Position: Q4 2020 in Review

Citadel Advisors sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 2,506,602 shares — an estimated $213M sold.

Citadel Advisors first reported a position in IMMU in Q2 2013 and held it in 26 quarters. The position peaked at $213M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Citadel Advisors reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 2,506,602 Immunomedics Inc shares in Q4 2020, an estimated $213M.
  • Citadel Advisors first reported a position in Immunomedics Inc in Q2 2013 and held it in 26 quarters.
  • Citadel Advisors's Immunomedics Inc position peaked at $213M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.